ABSTRACT
BACKGROUND: Adenovirus infections are prevalent in children. They usually cause a mild self-limited disease. However, this infection can be associated with considerable morbidity and mortality in specific populations, especially among immunocompromised children. Children with Down syndrome are susceptible to a higher frequency and increased severity of viral infections. Little is known about the severity and clinical course of adenovirus infections in children with Down syndrome. OBJECTIVES: To characterize hospitalized children diagnosed with Down syndrome and presenting with adenovirus infection. METHODS: We performed a retrospective review of children admitted with adenovirus from January 2005 to August 2014 from a single tertiary pediatric medical center in Israel. Data were compared between patients with and without Down syndrome. RESULTS: Among the 486 hospitalized children with adenoviral infection, 11 (2.28%) were diagnosed with Down syndrome. We found that children with Down syndrome were more likely to experience a higher incidence of complications (18.2% vs. 2.4%, P = 0.008), a higher rate of admissions to the intensive care unit (36.4% vs. 2.4%, P < 0.001), and more prolonged hospitalizations (17 ± 15.9 days compared to 4.46 ± 3.16, P = 0.025). CONCLUSIONS: Children with Down syndrome who were hospitalized with adenovirus infection represent a high-risk group and warrant close monitoring. If a vaccine for adenovirus becomes available, children with Down syndrome should be considered as candidates.
Subject(s)
Adenovirus Infections, Human , Critical Care , Down Syndrome , Hospitalization/statistics & numerical data , Length of Stay/statistics & numerical data , Adenoviridae/isolation & purification , Adenovirus Infections, Human/complications , Adenovirus Infections, Human/diagnosis , Adenovirus Infections, Human/epidemiology , Adenovirus Infections, Human/physiopathology , Child, Preschool , Critical Care/methods , Critical Care/statistics & numerical data , Down Syndrome/epidemiology , Down Syndrome/physiopathology , Down Syndrome/virology , Female , Hospitals, Pediatric , Humans , Incidence , Israel/epidemiology , Male , Risk Assessment , Severity of Illness Index , Tertiary Care Centers/statistics & numerical dataABSTRACT
Millions of patients seek medical attention for diarrhea, vomiting, nausea, and abdominal pain. In the current environment, it is important to recognize that these symptoms may be the only manifestation or may precede more serious systemic complications of COVID-19. Herein, we describe the first case of ischemic colitis (IC) in a young adult who presented with diarrhea and highlight the laboratory pitfalls for patients with COVID-19 presenting with gastrointestinal (GI) symptoms.
Subject(s)
COVID-19/virology , Colitis, Ischemic/diagnosis , Down Syndrome/physiopathology , Gastrointestinal Diseases/diagnosis , SARS-CoV-2/pathogenicity , Adolescent , COVID-19/diagnosis , Colitis, Ischemic/complications , Colitis, Ischemic/physiopathology , Diarrhea/complications , Diarrhea/virology , Down Syndrome/diagnosis , Down Syndrome/virology , Gastrointestinal Diseases/complications , Gastrointestinal Diseases/virology , Humans , MaleABSTRACT
Neurological complications of SARS-CoV-2 continue to be recognised. In children, neurological phenomenon has been reported generally in the acute infectious period. It is possible that SARS-CoV-2 could trigger an immune-mediated post-infectious phenomenon. Here, we present a unique case of post-infectious marantic cardiac lesion causing cerebrovascular accident in a patient with Down syndrome.
Subject(s)
COVID-19/complications , Down Syndrome , Nervous System Diseases/virology , Stroke/virology , Child , Down Syndrome/complications , Down Syndrome/virology , Humans , Inflammation/complications , Inflammation/virologyABSTRACT
SARS-CoV-2 infection has spread uncontrollably worldwide while it remains unknown how vulnerable populations, such as Down syndrome (DS) individuals are affected by the COVID-19 pandemic. Individuals with DS have more risk of infections with respiratory complications and present signs of auto-inflammation. They also present with multiple comorbidities that are associated with poorer COVID-19 prognosis in the general population. All this might place DS individuals at higher risk of SARS-CoV-2 infection or poorer clinical outcomes. In order to get insight into the interplay between DS genes and SARS-cov2 infection and pathogenesis we identified the genes associated with the molecular pathways involved in COVID-19 and the host proteins interacting with viral proteins from SARS-CoV-2. We then analyzed the overlaps of these genes with HSA21 genes, HSA21 interactors and other genes consistently differentially expressed in DS (using public transcriptomic datasets) and created a DS-SARS-CoV-2 network. We detected COVID-19 protective and risk factors among HSA21 genes and interactors and/or DS deregulated genes that might affect the susceptibility of individuals with DS both at the infection stage and in the progression to acute respiratory distress syndrome. Our analysis suggests that at the infection stage DS individuals might be more susceptible to infection due to triplication of TMPRSS2, that primes the viral S protein for entry in the host cells. However, as the anti-viral interferon I signaling is also upregulated in DS, this might increase the initial anti-viral response, inhibiting viral genome release, viral replication and viral assembly. In the second pro-inflammatory immunopathogenic phase of the infection, the prognosis for DS patients might worsen due to upregulation of inflammatory genes that might favor the typical cytokine storm of COVID-19. We also detected strong downregulation of the NLRP3 gene, critical for maintenance of homeostasis against pathogenic infections, possibly leading to bacterial infection complications.
Subject(s)
COVID-19/genetics , Down Syndrome/genetics , COVID-19/epidemiology , COVID-19/immunology , COVID-19/metabolism , Cytokine Release Syndrome/immunology , Down Syndrome/epidemiology , Down Syndrome/immunology , Down Syndrome/virology , Gene Regulatory Networks , Host Microbial Interactions , Humans , Inflammation/immunology , Pandemics , Protective Factors , Risk Factors , SARS-CoV-2/genetics , SARS-CoV-2/isolation & purification , Serine Endopeptidases/genetics , Serine Endopeptidases/metabolism , Transcriptome/geneticsABSTRACT
Patients with Down syndrome are at increased risk of respiratory syncytial virus- and H1N1-related death. Literature on COVID-19 in Down syndrome patients is unavailable thus far. We describe the clinical course of 4 patients with Down syndrome during an outbreak of COVID-19. In all four patients, disease course was severe, warranting hospital care in three patients, with fatal outcome in one patient. Another patient receives supportive care in our institution. Our case series is the first report on probable increased risk of life-threatening disease course of COVID-19 in patients with Down syndrome. Proper surveillance, the adherence of social distancing, and the use of personal protective equipment will be essential in reducing morbidity and mortality in our patients.
Subject(s)
COVID-19/complications , Down Syndrome/virology , Female , Humans , Middle Aged , SARS-CoV-2ABSTRACT
Torquetenovirus (TTV) viremia has been associated with increased mortality risk in the elderly population. This work aims to investigate TTV viremia as a potential biomarker of immunosenescence. We compared levels of circulating TTV in 1813 participants of the MARK-AGE project, including human models of delayed (offspring of centenarians [GO]) and premature (Down syndrome [DS]) immunosenescence. The TTV load was positively associated with age, cytomegalovirus (CMV) antibody levels, and the Cu/Zn ratio and negatively associated with platelets, total cholesterol, and total IgM. TTV viremia was highest in DS and lowest in GO, with intermediate levels in the SGO (spouses of GO) and RASIG (Randomly Recruited Age-Stratified Individuals From The General Population) populations. In the RASIG population, TTV DNA loads showed a slight negative association with CD3+T-cells and CD4+T-cells. Finally, males with ≥4log TTV copies/mL had a higher risk of having a CD4/CD8 ratio<1 than those with lower viremia (odds ratio [OR] = 2.85, 95% confidence interval [CI]: 1.06-7.62), as well as reduced CD3+ and CD4+T-cells compared to males with lower replication rates (<4log), even after adjusting for CMV infection. In summary, differences in immune system preservation are reflected in the models of delayed and premature immunosenescence, displaying the best and worst control over TTV replication, respectively. In the general population, TTV loads were negatively associated with CD4+ cell counts, with an increased predisposition for an inverted CD4/CD8 ratio for individuals with TTV loads ≥4log copies/mL, thus promoting an immune risk phenotype.
Subject(s)
DNA Virus Infections/virology , Immunosenescence/immunology , Torque teno virus/immunology , Viremia/virology , Adult , Age Factors , Aged , Cross-Sectional Studies , Cytomegalovirus/immunology , DNA Virus Infections/immunology , Down Syndrome/immunology , Down Syndrome/virology , Europe , Female , Humans , Lymphocyte Count , Male , Middle Aged , Prevalence , Viral Load , Viremia/immunologyABSTRACT
Diffuse large B-cell Lymphoma (DLBCL) secondary to a chronic severe Epstein-Barr virus (EBV) infection has not been previously described in a patient with trisomy 21. Here we report the case of a 14-year-old girl with trisomy 21 with impaired control of EBV and DLBCL. She was cured with dose-adapted chemotherapy and hematopoietic stem cell transplantation without severe treatment-related toxicity. We describe the first case of EBV-positive DLBCL in a patient with trisomy 21 and we propose a treatment modality for this rare entity.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Down Syndrome/therapy , Epstein-Barr Virus Infections/therapy , Hematopoietic Stem Cell Transplantation/methods , Herpesvirus 4, Human/isolation & purification , Lymphoma, Large B-Cell, Diffuse/therapy , Adolescent , Combined Modality Therapy , Down Syndrome/complications , Down Syndrome/genetics , Down Syndrome/virology , Epstein-Barr Virus Infections/complications , Epstein-Barr Virus Infections/virology , Female , Humans , Lymphoma, Large B-Cell, Diffuse/complications , Lymphoma, Large B-Cell, Diffuse/genetics , Lymphoma, Large B-Cell, Diffuse/virology , PrognosisABSTRACT
BACKGROUND: Respiratory syncytial virus (RSV) infection in childhood, particularly in premature infants, is associated with significant morbidity and mortality. OBJECTIVES: To compare the hospitalization rates due to RSV infection and severity of disease between infants with and without Down syndrome (DS) born at term and without other associated risk factors for severe RSV infection. PATIENTS/METHODS: In a prospective multicentre epidemiological study, 93 infants were included in the DS cohort and 68 matched by sex and data of birth (±1 week) and were followed up to 1 year of age and during a complete RSV season. RESULTS: The hospitalization rate for all acute respiratory infection was significantly higher in the DS cohort than in the non-DS cohort (44.1% vs 7.7%, P<.0001). Hospitalizations due to RSV were significantly more frequent in the DH cohort than in the non-DS cohort (9.7% vs 1.5%, P=.03). RSV prophylaxis was recorded in 33 (35.5%) infants with DS. The rate of hospitalization according to presence or absence of RSV immunoprophylaxis was 3.0% vs 15%, respectively. CONCLUSIONS: Infants with DS showed a higher rate of hospitalization due to acute lower respiratory tract infection and RSV infection compared to non-DS infants. Including DS infants in recommendations for immunoprophylaxis of RSV disease should be considered.
Subject(s)
Down Syndrome/complications , Down Syndrome/virology , Epidemiologic Studies , Hospitalization/statistics & numerical data , Respiratory Syncytial Virus Infections/complications , Respiratory Syncytial Virus Infections/epidemiology , Acute Disease/epidemiology , Antiviral Agents/therapeutic use , Down Syndrome/epidemiology , Female , Follow-Up Studies , Humans , Infant , Infant, Newborn , Male , Palivizumab/therapeutic use , Prospective Studies , Respiratory Syncytial Virus Infections/drug therapy , Respiratory Syncytial Virus Infections/virology , Respiratory Syncytial Virus, Human/isolation & purification , Risk FactorsABSTRACT
BACKGROUND: Down syndrome (DS) is a risk factor for respiratory syncytial virus (RSV) hospitalization, but little is known about prophylaxis in these children. METHODS: CARESS is a prospective registry of children who received ≥1 dose of palivizumab during the 2006-2012 RSV seasons across 32 sites in Canada. The objective was to compare respiratory illness hospitalization and RSV hospitalization (RSVH) hazard ratios in DS children aged <2 years who received palivizumab versus children who received prophylaxis for standard indications (SI) and for other medical illnesses (MI). RESULTS: 13,310 children were enrolled; DS (600; 4.5%), SI (11,081; 83.3%) and MI (1629, 12.2%), with DS children increasing over the duration from 0.1% (2006) to 4.5% (2012). Participants were significantly different in mean birth weight, gestational and enrollment age and risk factors. Children in each group received an average of 4.3 ± 1.4 (DS), 4.1 ± 1.6 (SI) and 4.5 ± 1.4 (MI) palivizumab injections per RSV season, with DS, differing significantly from SI [F(2, 13,307) = 43.6, P = 0.01] but not MI [F(2, 13 307) = 43.6, P = 0.07]. Compliance rates were similar across the groups. While a significantly greater proportion of SI children had RIHs compared with DS, [hazard ratio: 0.64 (0.48-0.84); P = 0.001] hazard ratios were similar for DS and MI. RSVH incidence rates were: 1.53%, 1.45% and 2.27% for DS, SI and MI, respectively. Neither group nor compliance affected time to RSVH. CONCLUSIONS: The proportion of DS children who received palivizumab in CARESS has increased almost 45-fold. RSVH rates were low in DS following prophylaxis and hazards were similar to those found in SI and MI.
Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Antiviral Agents/therapeutic use , Down Syndrome/epidemiology , Down Syndrome/virology , Respiratory Syncytial Virus Infections/epidemiology , Respiratory Syncytial Virus Infections/prevention & control , Antibiotic Prophylaxis , Canada/epidemiology , Female , Hospitalization , Humans , Infant , Male , Palivizumab , Prospective Studies , Treatment OutcomeABSTRACT
BACKGROUND: There are incomplete data on the global burden of viral lower respiratory tract infection, in particular the role of Respiratory Syncytial Virus, in children requiring health services. FINDINGS: In this study set in a large urban area of southern China from 1 January 2007 to 31 December 2010, children 1 month to 14 years of age with RSV-associated "severe" or "very severe pneumonia" according to World Health Organization definitions, and meeting local criteria for admission to the pediatric intensive care unit, were followed for the course of their admission. The median age was 3 months and 79% (135/171) of children with RSV were under six months of age. All children needed supplemental oxygen, and 22% required mechanical ventilatory support. The mortality rate was 3.5%. In multivariate analysis, congenital heart disease and Trisomy 21 were associated with death. CONCLUSIONS: Children admitted to an intensive care unit with RSV-associated severe/very pneumonia in a large urban setting in southern China were most commonly ≤ six months old and almost one quarter of these had respiratory failure. The overall mortality rate was 3.5%. RSV vaccine strategies that would protect children from early infancy are urgently needed.
Subject(s)
Down Syndrome/physiopathology , Heart Defects, Congenital/physiopathology , Hospitalization/statistics & numerical data , Pneumonia, Viral/physiopathology , Respiratory Syncytial Virus Infections/physiopathology , Respiratory Syncytial Viruses/pathogenicity , Adolescent , Child , Child, Preschool , China/epidemiology , Comorbidity , Down Syndrome/mortality , Down Syndrome/virology , Female , Heart Defects, Congenital/mortality , Heart Defects, Congenital/virology , Humans , Infant , Intensive Care Units, Pediatric , Male , Pneumonia, Viral/mortality , Pneumonia, Viral/virology , Respiration, Artificial , Respiratory Syncytial Virus Infections/mortality , Respiratory Syncytial Virus Infections/virology , Risk Factors , Survival Analysis , Urban PopulationABSTRACT
We compared prevalence of hospitalization, endotracheal intubation, and death among case-patients with and without Down syndrome during pandemic (H1N1) 2009 in Mexico. Likelihoods of hospitalization, intubation, and death were 16-fold, 8-fold, and 335-fold greater, respectively, for patients with Down syndrome. Vaccination and early antiviral drug treatment are recommended during such epidemics.
Subject(s)
Down Syndrome/virology , Influenza A Virus, H1N1 Subtype/isolation & purification , Influenza, Human/complications , Pandemics , Adolescent , Adult , Child , Down Syndrome/epidemiology , Female , Humans , Influenza, Human/epidemiology , Influenza, Human/virology , Male , Young AdultSubject(s)
Decision Making , Down Syndrome/virology , Legal Guardians/psychology , Pneumonia, Viral/complications , Siblings/psychology , Advance Directives , Anecdotes as Topic , Critical Care/psychology , Down Syndrome/therapy , Humans , Legal Guardians/legislation & jurisprudence , Male , Middle Aged , Pneumonia, Viral/therapyABSTRACT
The high incidence of Hepatitis A and B in institutionalized patients with Down Syndrome (DS) is not fully understood. Under poor hygienic conditions, immunological alterations might predispose individuals to these infections. Sixty three DS children between 1 and 12 years old living at home with their families were examined for anti-HAV and compared to age-matched controls (64 healthy children). This cross-sectional study was carried out from May 1999 to April 2000 at the Hospital de Clínicas of Porto Alegre, southern Brazil. Groups were compared in terms of age, sex, skin color, and family income (> R$ 500 and < R $ 500/month) by the chi-square test, with Yates' correction and for the prevalence of anti-HAV (Fisher's exact test). In the DS group (n=63), the mean age was 4.4 +/- 3.3 years, 94% of the patients were white and 51% were female. Family income was < or = R$ 500/month in 40 cases (63%). In the control group (n=64), the mean age was 4.8 +/- 2.7 years, 81% of the patients were white and 56% were female. Family income was < or = R$ 500 in 20 patients (31%). DS children's families had a significantly lower income (P<0.0005). In the DS group there were 6 positive (9.5%) anti-HAV cases, and all came from low-income families (less than R$ 500/ month). In the control group, 3 cases (4.7%) were positive for anti-HAV (two were from a low-income family and one was from a higher income family). These differences were not significant. Our data indicate that Hepatitis A is not a special risk for mentally retarded DS outpatients, even in a developing country like Brazil.
Subject(s)
Down Syndrome/immunology , Hepatitis A Antibodies/blood , Hepatitis A/immunology , Brazil , Case-Control Studies , Child , Child, Preschool , Cross-Sectional Studies , Down Syndrome/virology , Female , Hepatitis A/blood , Hepatitis A/complications , Humans , Infant , Male , Seroepidemiologic Studies , Socioeconomic FactorsABSTRACT
The peripheral and central nervous system are harbouring herpes simplex virus type 1 (HSV-1) and this virus has been proposed to be implicated in the aetiology of Alzheimer's disease (AD). We tested whether the HSV-1 genome is found indeed in the brain of controls, patients with AD and Down syndrome (DS) and whether HSV-1 infectious proteins in brain were induced. Moreover, we tested whether interleukin (IL)-6, a marker for neuroinflammation, is found in brains of AD and DS. HSV-1 glycoprotein D gene, as well as viral phosphoprotein and glycoprotein were detected in all brain samples. IL-6 was detectable in seven out of the eight AD and all of the eight DS patients, but only three out of ten controls in the frontal cortex. IL-6 in cerebellum was detectable in all AD and DS patients, but only three out of nine controls. In conclusion, we propose that the detection of HSV-1 genome and HSV-1 inducible protein IL-6 not only shows the presence in human brain, but may indicate a role for HSV-1 in the process of neuroinflammation and apoptosis, known to occur in both neurodegenerative disorders, AD and DS.
Subject(s)
Alzheimer Disease/virology , Cerebellum/virology , Down Syndrome/virology , Frontal Lobe/virology , Herpesvirus 1, Human/isolation & purification , Alzheimer Disease/blood , Alzheimer Disease/pathology , Cerebellum/pathology , Down Syndrome/blood , Down Syndrome/pathology , Frontal Lobe/pathology , Glycoproteins/analysis , Herpesvirus 1, Human/genetics , Herpesvirus 1, Human/immunology , Humans , Interleukin-6/metabolism , Phosphoproteins/analysis , Viral Envelope Proteins/geneticsABSTRACT
This study evaluates the transmission of CMV infection in 120 children aged 1 to 15 years with Down syndrome who attended a day-care center for handicapped children in São Paulo, Brazil. A blood sample was obtained from each children at the beginning of the study for detection of IgG and IgM cytomegalovirus (CMV) antibodies by an immunofluorescence assay. Samples of saliva and urine were obtained every 3 months from the children with CMV antibodies to detect shedding of the virus by culture in human foreskin fibroblasts, by detection of pp65 CMV-antigen and by a nested PCR assay. The prevalence of anti CMV-IgG antibodies was 76.6% (92/120), and IgM anti-CMV antibodies were detected in 13% (12/92) of the seropositive children. During the first viral evaluation, CMV was detected in the urine and/or saliva in 39/90 (43.3%) of the seropositive children. In the second and third evaluations, CMV was detected in 41/89 (46%) and in 35/89 (39.3%) children, respectively. Detection of CMV was shown both in urine and saliva in 28/39 (71.8%), 19/41(46.3%) and 20/35 (57.1%) of the children excreting the virus, respectively. Additionally, in 3(3/4)9 (67.4%) of the excreters CMV could be demonstrated in urine or saliva in at least two out of the three virological evaluations carried out sequentially in a six month period. Of the 28 initially seronegative children, 26 were re-examined for anti-CMV IgG antibodies about 18 months after the negative sample; seroconversion was found in 10/26 (38.5%). Taking all 536 samples of urine or saliva examined by virus culture and pp65 antigen detection during the study into account, 159 (29.6%) were positive by virus culture and 59 (11%) gave a positive result with the pp65 assay. These data demonstrate the high prevalence of CMV shedding and the high risk of CMV infection in children with Down syndrome attending a day-care center for mentally handicapped patients. The virus culture was more sensitive than the pp65 CMV antigen assay for CMV detection in both urine and saliva samples.
Subject(s)
Child Day Care Centers/statistics & numerical data , Cytomegalovirus Infections/epidemiology , Down Syndrome/virology , Adolescent , Antibodies, Viral/isolation & purification , Brazil/epidemiology , Child , Child, Preschool , Cytomegalovirus/immunology , Cytomegalovirus Infections/transmission , Humans , Immunoglobulin G/isolation & purification , Immunoglobulin M/isolation & purification , Infant , Polymerase Chain Reaction , Prevalence , Virus SheddingABSTRACT
This study evaluates the transmission of CMV infection in 120 children aged 1 to 15 years with Down syndrome who attended a day-care center for handicapped children in São Paulo, Brazil. A blood sample was obtained from each children at the beginning of the study for detection of IgG and IgM cytomegalovirus (CMV) antibodies by an immunofluorescence assay. Samples of saliva and urine were obtained every 3 months from the children with CMV antibodies to detect shedding of the virus by culture in human foreskin fibroblasts, by detection of pp65 CMV-antigen and by a nested PCR assay. The prevalence of anti CMV-IgG antibodies was 76.6 per cent (92/120), and IgM anti-CMV antibodies were detected in 13 per cent (12/92) of the seropositive children. During the first viral evaluation, CMV was detected in the urine and/or saliva in 39/90 (43.3 per cent) of the seropositive children. In the second and third evaluations, CMV was detected in 41/89 (46 per cent) and in 35/89 (39.3 per cent) children, respectively. Detection of CMV was shown both in urine and saliva in 28/39 (71.8 per cnet), 19/41(46.3 per cent) and 20/35 (57.1 per cent) of the children excreting the virus, respectively...
Subject(s)
Humans , Infant , Child, Preschool , Child , Adolescent , Child Day Care Centers , Cytomegalovirus Infections/epidemiology , Down Syndrome/virology , Cytomegalovirus Infections/transmissionABSTRACT
The objective of this study was to examine whether the prevalence of hepatitis C, like hepatitis B, is increased among the mentally retarded in Denmark. The prevalence of serological markers of hepatitis B and C was examined in an institution for the mentally retarded. A total of 126 out of 178 inhabitants (71%) with a median age of 49 years (range 23-78) participated. All subjects were anti-HCV-negative by third generation ELISA antibody test. A total of 45 (35.7%) subjects were anti-HBc-positive and 10 (7.9%) were HBsAg-positive. Among subjects with Down's syndrome (n = 20), 55% were anti-HBc-positive and 30% were HBsAg-positive as compared to 32% and 3.8% respectively among others. In conclusion, hepatitis C infection seems to be uncommon among mentally retarded persons in Denmark and the risk of acquiring infection not significantly increased as compared to that of the general population. The prevalence of serological markers for hepatitis B was high and comparable to previous studies in this population.